A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Nihon Medi-Physics Co.,Ltd.

Nihon Medi-Physics Co.,Ltd.

Table of Contents

Nihon Medi-Physics Co.,Ltd. handles radiopharmaceuticals, other pharmaceuticals, and regenerative medicine products. This overview summarizes the features of the company’s nonclinical studies, a representative example of disease models, and case examples. Use this information to support selection of a contract research partner.

Features of Nihon Medi-Physics Co.,Ltd.’ Non-Clinical Contract Research Services

Advanced PET imaging technology

Through nonclinical PET imaging studies, Nihon Medi-Physics Co.,Ltd. uses radiolabeled compounds (radioisotopes; RI) to visualize in vivo pharmacokinetics in real time. These studies can evaluate tissue and cellular uptake and metabolism of development candidate compounds. This capability plays an important role in research related to cancer and brain function and can support efficacy assessment and dose selection for new drugs.

Radiopharmaceutical supply

Nihon Medi-Physics Co.,Ltd. manufactures and supplies radiopharmaceuticals used to support the diagnosis of Alzheimer’s disease and Parkinson’s disease, including [18F]flutemetamol and [123I]ioflupane for PET and SPECT imaging. These products support diagnostic accuracy and provide data that can inform new drug development.

Theranostics initiatives

Nihon Medi-Physics Co.,Ltd. also focuses on research and development toward theranostics—the integration of treatment and diagnosis. This approach uses radiopharmaceuticals to support real-time monitoring of a patient’s condition during treatment.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Held by Nihon Medi-Physics Co.,Ltd.

No description of the disease models was found.

Examples of Non-Clinical Studies by Nihon Medi-Physics Co.,Ltd.

Evaluation of D2 Receptor Occupancy Using [¹¹C]raclopride

[¹¹C]raclopride, a radiolabeled radiotracer, is used primarily for dopamine D2 receptor studies and diagnostic PET imaging. This study evaluates the extent to which this tracer binds to dopamine D2 receptors in the brain to assess D2 receptor occupancy. A higher occupancy level suggests that the drug is effectively engaging the receptors and is useful for assessing D2 receptor status in studies of psychiatric disorders such as schizophrenia.

Reference: Japan Medifix official websitehttps://www.nmp.co.jp/corpo/business/non-clinical_pet.html

Evaluation of 5-HT2A (Serotonin 2A) Receptor Binding Using [¹⁸F]altanserin

[¹⁸F]altanserin, used in 5-HT2A (serotonin 2A) receptor research and PET imaging, measures and analyzes the degree to which this radiotracer binds to 5-HT2A receptors in the brain. It is useful for quantitative evaluation of the effects of drugs that act on 5-HT2A receptors, such as antidepressants and antipsychotics, and for studying the role of 5-HT2A receptors in psychiatric and neurological disorders such as depression, schizophrenia, and Alzheimer’s disease.

Reference: Japan Medifix official websitehttps://www.nmp.co.jp/corpo/business/non-clinical_pet.html

Nihon Medi-Physics Co.,Ltd. Corporate Information

Nihon Medi-Physics Co.,Ltd. develops, manufactures, and sells radiopharmaceuticals, mainly in the field of nuclear medicine. Its main business areas are PET and SPECT examinations using diagnostic radiopharmaceuticals, as well as cancer treatment using therapeutic radiopharmaceuticals. In addition, the company provides contract services for nonclinical PET imaging studies and contract manufacturing of radiopharmaceuticals.

Address	3-4-10 Shinsuna, Koto-ku, Tokyo, Japan
Tel	03-5634-7006
Website	https://www.nmp.co.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us